Compare · CDIO vs ORKA
CDIO vs ORKA
Side-by-side comparison of Cardio Diagnostics Holdings Inc. (CDIO) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDIO and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $3.86B, about 656.0x CDIO ($5.9M).
- Over the past year, CDIO is down 58.9% and ORKA is up 409.4% - ORKA leads by 468.3 points.
- ORKA has been more active in the news (11 items in the past 4 weeks vs 2 for CDIO).
- ORKA has more recent analyst coverage (11 ratings vs 0 for CDIO).
PerformanceCDIO-58.91%ORKA+409.39%
2025-06-09+0.00%2026-06-08
- Company
- Cardio Diagnostics Holdings Inc.
- Oruka Therapeutics Inc.
- Price
- $1.96-0.51%
- $64.03+6.51%
- Market cap
- $5.9M
- $3.86B
- 1M return
- +7.69%
- +0.02%
- 1Y return
- -58.91%
- +409.39%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 2
- 11
- Recent ratings
- 0
- 11
Latest CDIO
- Cardio Diagnostics Holdings, Inc. to Showcase Precision Cardiovascular Solutions at Four National Benefits Conferences in June
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Meesha Dogan, CEO of Cardio Diagnostics Holdings Inc.
- SEC Form 10-Q filed by Cardio Diagnostics Holdings Inc.
- IBN Initiates Coverage of Cardio Diagnostics Holdings Inc.
- SEC Form 4 filed by Fung Peter K
- SEC Form 4 filed by Betts Wendy J
- SEC Form 4 filed by Intrater James
- SEC Form 4 filed by Burton Paul Frederick
- SEC Form 10-K filed by Cardio Diagnostics Holdings Inc.
- Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest ORKA
- Oruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Ball Kristine M
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- Oruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- Director Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)